Scale -


  • Revenue is 708 Rs Cr; Continuous Growth over 3 years; 5 Year CAGR is 70 %
  • Ebitda is 173 Rs Cr; Continuous Growth over 3 years; in Top Quartile; 5 Year CAGR is 49 %
  • PBT is 41.46 Rs Cr; Continuous Growth over 3 years; in Top Quartile; 5 Year CAGR is 76 %; Annual Decline is -34 %
  • Quarterly Profit is 30.76 Rs Cr; Continuous Growth over 3 Quarters
  • PAT is 115 Rs Cr; in Top Quartile; 5 Year CAGR is 65 %; Annual Decline is -37 %

Profitability -


  • PBDIT Margin is 24.4 %; in Top Quartile; 5 Year CAGR is -12 %
  • PAT Margin is 16.27 %; in Top Quartile; Annual Decline is -42 %
  • Quarterly Ebitda Margin is 22 %; in Top Quartile

Return -


  • ROCE is 23.9 %; in Top Quartile; 5 Year CAGR is 16 %
  • ROA is 14.52 %; in Top Quartile; Annual Decline is -48 %
  • ROE is 19.02 %; in Top Quartile; Annual Decline is -45 %; 5 Year CAGR is -21 %
  • Asset Turnover is 98 %; in Top Quartile; 5 Year CAGR is -75 %

Efficiency -


  • Current Ratio is 3.48; in Top Quartile; 5 Year CAGR is 29 %
  • Quick Ratio is 2.71; in Top Quartile; 5 Year CAGR is 30 %

Solvancy -


  • Debt/Equity is 0.03; 5 Year CAGR is -73 %
  • Long term Debt is 13.33 Rs Cr; 5 Year CAGR is -48 %
  • Total Debt is 20 Rs Cr; 5 Year CAGR is -41 %
  • Contingent Liabilities is 31.92 Rs Cr; Annual Growth is 110 %; Continuous Growth over 3 years; 5 Year CAGR is 29 %

Quality -


  • Exceptional Items/PBT is 3 %; Annual Decline is -93 %; in Top Quartile
  • Change in Inventories/Total Expenses is -4 %; Annual Decline is -326 %; Continuous Decline over 3 years; in Bottom Quartile
  • Operating cashflow/PAT is 49 %; Continuous Growth over 3 years
  • Other Expenses/Total Expenses is 29 %; Continuous Decline over 3 years; in Top Quartile
  • Operating cashflow/ebitda is 33 %; Annual Decline is -28 %
  • Current Tax/PAT is 30 %; Continuous Growth over 3 years; 5 Year CAGR is 61 %

Quarterly Results- overall

Annual Results- Scale

Annual Results- Liquidity

Annual Results- Profitability/Return

Annual Results- Valuation

External Ecosystem


Sector
Major Subsidiaries/Associates
Key Clients

Products


Products
Product details

Operations


Capacity/ Production
Key Facilities
Key Certifications
Raw materials
Recent News
RPG Life Reports Gross Margin Improvement Of 260 Basis Points Year Over Year
RPG Life Sciences Posts 16.5% Revenue Growth To ?211.6 Crore In Q2 FY27; Adjusted EBITDA Rises 15%
RPG Life Sciences Q2: net profit stands at ?28.2 Cr on 16.5% revenue growth; API subsidiary restructuring and acquisitions shape earnings
RPG Life Sciences Limited (RPGLIFE) share price — eduinvesting
RPG Life Sciences Reports Q2 Standalone Net Profit Of ?23.3 Crore Vs ?36.9 Crore YoY
RPG Life Sciences RPGLIFE Q2 FY27 Results Board Meeting
RPGLIFE: Acquisitions lifted Q2 revenue, while H1 profit eased year over year
RPGLIFE: H1 revenue rose 16.2%, API sales surged 58.5%, and market cap climbed 64%
Anti-cancer drug prices slashed for 543 brands; new MRPs effective from Nov 9
NPPA releases Revised MRP for 543 brands of Anti-Cancer Medicines; List to be updated on continual basis; New Prices Effective from November 9, 2026
NPPA revises MRP of 543 anti-cancer medicine brands; new prices effective from November 9